Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Solène Huard

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Trends in Cell Biology|January 24, 2021
CARM1/PRMT4: Making Its Mark beyond Its Function as a Transcriptional CoactivatorSamyuktha Suresh, Solène Huard, Thierry Dubois
Nucleic Acids Research|May 24, 2022
Hexokinase 2 is a transcriptional target and a positive modulator of AHR signallingManon Watzky, Solène Huard, Ludmila Juricek, et al.
Breast Cancer (Dove Medical Press)|November 13, 2023
Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast CancersRayan Dakroub, Solène Huard, Yara Hajj-Younes, et al.
Cancer Gene Therapy|May 15, 2023
Respective roles of Pik3ca mutations and cyproterone acetate impregnation in mouse meningioma tumorigenesisPierre-Cyril Cômes, Tuan Le Van, Suzanne Tran, et al.
Cancers|January 21, 2022
PRMT1 Regulates EGFR and Wnt Signaling Pathways and Is a Promising Target for Combinatorial Treatment of Breast CancerSamyuktha Suresh, Solène Huard, Amélie Brisson, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Trends in Cell Biology|January 24, 2021
CARM1/PRMT4: Making Its Mark beyond Its Function as a Transcriptional CoactivatorSamyuktha Suresh, Solène Huard, Thierry Dubois
Nucleic Acids Research|May 24, 2022
Hexokinase 2 is a transcriptional target and a positive modulator of AHR signallingManon Watzky, Solène Huard, Ludmila Juricek, et al.
Breast Cancer (Dove Medical Press)|November 13, 2023
Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast CancersRayan Dakroub, Solène Huard, Yara Hajj-Younes, et al.
Cancer Gene Therapy|May 15, 2023
Respective roles of Pik3ca mutations and cyproterone acetate impregnation in mouse meningioma tumorigenesisPierre-Cyril Cômes, Tuan Le Van, Suzanne Tran, et al.
Cancers|January 21, 2022
PRMT1 Regulates EGFR and Wnt Signaling Pathways and Is a Promising Target for Combinatorial Treatment of Breast CancerSamyuktha Suresh, Solène Huard, Amélie Brisson, et al.
Pageof 1